8-K current report · filed Aug 13, 2026

Atrium Therapeutics, Inc. (RNA) 8-K Current Report: August 13, 2026

Item EX-99.1Item 2.02RNA overview

Short answer

Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results announced for quarter ended June 30, 2026.

Atrium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results announced for quarter ended June 30, 2026
  • Full financial results available in Exhibit 99.1 press release
  • Investor focus: quarterly performance, cash position and clinical-development funding implications

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $20.2M, or $1.18 per share, versus $12.9M, or $0.75, year-over-year
  • FDA IND clearance enables ATR 1072’s Corventis Phase 1/2 trial, targeting approximately 37 PRKAG2 syndrome participants
  • Corventis first enrollment remains expected by year-end 2026, with initial proof-of-concept data targeted for second half 2027
  • BMS collaboration generated a $15M milestone payment in August, to be recognized in Q3 2026
  • Cash, equivalents and short-term investments totaled $263.9M, supporting planned operations through mid-2028 including the BMS payment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Atrium Therapeutics, Inc. 8-K filings

Get the next RNA 8-K as it lands

Follow RNA for push alerts, or ask the research agent what this filing means.